While strategies of CAR-T cell targeting of CD19 for AML have been limited, one study for CD19+ AML patients has made it to phase 2 & 3 clinical trial and is actively recruiting at the Sheba Medical Center, Israel. The gene discussed is CD19; the disease is acute myeloid leukemia.